Arcutis Biotherapeutics Stock Short Ratio
| ARQT Stock | USD 11.71 0.20 1.74% |
Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.
Arcutis | Short Ratio |
Arcutis Biotherapeutics Company Short Ratio Analysis
Arcutis Biotherapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Arcutis Biotherapeutics Short Ratio | 11.20 X |
Most of Arcutis Biotherapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcutis Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcutis Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcutis Biotherapeutics is extremely important. It helps to project a fair market value of Arcutis Stock properly, considering its historical fundamentals such as Short Ratio. Since Arcutis Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcutis Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcutis Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Arcutis Biotherapeutics has a Short Ratio of 11.2 times. This is 187.18% higher than that of the Biotechnology sector and 51.15% higher than that of the Health Care industry. The short ratio for all United States stocks is 180.0% lower than that of the firm.
Arcutis Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcutis Biotherapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics of similar companies.Arcutis Biotherapeutics is currently under evaluation in short ratio category among its peers.
Arcutis Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 830.3M | 1.0B | 1.0B | 223.9M | 257.4M | 244.6M | |
| Enterprise Value | 767.3M | 943.2M | 1.0B | 341.4M | 392.6M | 373.0M |
Arcutis Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcutis Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Arcutis Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcutis Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcutis Biotherapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.5 M | Ensign Peak Advisors Inc | 2024-09-30 | 2.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 2.3 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-06-30 | 2 M | Deutsche Bank Ag | 2024-06-30 | 1.9 M | Stempoint Capital Lp | 2024-09-30 | 1.8 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.7 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.6 M | J. Goldman & Co Lp | 2024-09-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 11.7 M | Suvretta Capital Management, Llc | 2024-06-30 | 10 M |
Arcutis Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.25 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 25.02 M | ||||
| Price To Book | 8.75 X | ||||
| Price To Sales | 9.88 X | ||||
| Revenue | 59.61 M | ||||
| Gross Profit | 2.93 M | ||||
| EBITDA | (227.43 M) | ||||
| Net Income | (262.14 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 205.92 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (247.06 M) | ||||
| Short Ratio | 11.20 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 296 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.37 B | ||||
| Total Asset | 341.37 M | ||||
| Retained Earnings | (981.9 M) | ||||
| Working Capital | 283.76 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
| Net Asset | 341.37 M |
About Arcutis Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.